Trial
NCT03972709
A Study Assessing the Safety, Tolerability, and Efficacy of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Genentech, Inc.
Collaborators
—
Condition
Macular Degeneration, Age-Related
Intervention
Galegenimab
Why stopped
The benefit to risk balance did not support further treatment with galegenimab (FHTR2163).
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-03-27